BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 17065181)

  • 21. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
    Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
    Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes in children with idiopathic pulmonary arterial hypertension.
    Yung D; Widlitz AC; Rosenzweig EB; Kerstein D; Maislin G; Barst RJ
    Circulation; 2004 Aug; 110(6):660-5. PubMed ID: 15289375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival.
    Sajan I; Manlhiot C; Reyes J; McCrindle BW; Humpl T; Friedberg MK
    Am Heart J; 2011 Sep; 162(3):562-8. PubMed ID: 21884877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
    Sitbon O; Humbert M; Nunes H; Parent F; Garcia G; Hervé P; Rainisio M; Simonneau G
    J Am Coll Cardiol; 2002 Aug; 40(4):780-8. PubMed ID: 12204511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
    Nakayama T; Ishikita T; Matsuura H; Saji T
    J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Sitbon O; Delcroix M; Bergot E; Boonstra AB; Granton J; Langleben D; Subías PE; Galiè N; Pfister T; Lemarié JC; Simonneau G
    Am Heart J; 2014 Feb; 167(2):210-7. PubMed ID: 24439982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol.
    Kuhn KP; Byrne DW; Arbogast PG; Doyle TP; Loyd JE; Robbins IM
    Am J Respir Crit Care Med; 2003 Feb; 167(4):580-6. PubMed ID: 12446266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
    Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
    Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous intravenous epoprostenol in pulmonary hypertension: the Israel experience.
    Bendayan D; Fink G; Aravot D; Ygla M; Bendov I; Bliden L; Nir A; Kramer MR
    Isr Med Assoc J; 2002 Apr; 4(4):255-8. PubMed ID: 12001697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Living-donor lobar lung transplantation for pulmonary arterial hypertension after failure of epoprostenol therapy.
    Date H; Kusano KF; Matsubara H; Ogawa A; Fujio H; Miyaji K; Okazaki M; Yamane M; Toyooka S; Aoe M; Sano Y; Hanazaki M; Goto K; Kasahara S; Sano S; Ohe T
    J Am Coll Cardiol; 2007 Aug; 50(6):523-7. PubMed ID: 17678735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral.
    Badagliacca R; Pezzuto B; Poscia R; Mancone M; Papa S; Marcon S; Valli G; Sardella G; Ferrante F; Iacoboni C; Parola D; Fedele F; Vizza CD
    J Heart Lung Transplant; 2012 Apr; 31(4):364-72. PubMed ID: 22289484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.
    Fisher KA; Serlin DM; Wilson KC; Walter RE; Berman JS; Farber HW
    Chest; 2006 Nov; 130(5):1481-8. PubMed ID: 17099027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan.
    Safdar Z
    Respir Med; 2009 Nov; 103(11):1688-92. PubMed ID: 19539456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.
    Siehr SL; Ivy DD; Miller-Reed K; Ogawa M; Rosenthal DN; Feinstein JA
    J Heart Lung Transplant; 2013 May; 32(5):546-52. PubMed ID: 23453572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Ten years' experience in continuous intravenous epoprostenol therapy in severe pulmonary arterial hypertension].
    Pombo Jiménez M; Escribano Subías P; Tello de Meneses R; Gómez-Sánchez MA; Delgado Jiménez J; Dalmau González-Gallarza R; Lázaro Salvador M; Hernández Rodríguez I; Tascón Pérez J; Sáenz de la Calzada C
    Rev Esp Cardiol; 2003 Mar; 56(3):230-5. PubMed ID: 12622952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children.
    Hislop AA; Moledina S; Foster H; Schulze-Neick I; Haworth SG
    Eur Respir J; 2011 Jul; 38(1):70-7. PubMed ID: 21177841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.
    Hiremath J; Thanikachalam S; Parikh K; Shanmugasundaram S; Bangera S; Shapiro L; Pott GB; Vnencak-Jones CL; Arneson C; Wade M; White RJ;
    J Heart Lung Transplant; 2010 Feb; 29(2):137-49. PubMed ID: 20022264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
    Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.
    Kylhammar D; Persson L; Hesselstrand R; Rådegran G
    Scand Cardiovasc J; 2014 Aug; 48(4):223-33. PubMed ID: 24912571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pulmonary arterial hypertension treated with prostacyclin or calcium blockers].
    Andreassen AK; Geiran O; Madsen S; Hognestad A; Simonsen S
    Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3393-6. PubMed ID: 14713978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.